FDA ENDS Authorization: What Vape Makers Must Know

FDA announced on May 5, 2026 that it had authorized the marketing of four Glas electronic nicotine delivery system (ENDS) products — Silver, Black, Gold, and Sapphire — through the premarket tobacco product application (PMTA) pathway, according to the agency's press release (FDA Expands Market Access, Authorizes New ENDS Products). Two of those four are not routine at all: Gold (mango) and Sapphire (blueberry) are the first non-tobacco, non-menthol flavored ENDS products FDA has ever cleared for the U.S. market. FDA's stated basis leaned heavily on device-access-restriction technology built into the products — government-ID verification, smartphone pairing, and biometric checks — as evidence the devices could still limit youth access despite the flavor profile. That combination, not the brand name on the press release, is the actual news: it's the clearest signal yet of what FDA will accept as youth-access mitigation strong enough to authorize a flavored product, and it matters more to your business than the headline.

I've spent enough time inside FDA's regulatory pathways — PMTA, 510(k), NDA, food facility registration — to know that the interesting story is rarely the announcement itself. It's what the announcement implies about enforcement posture, review priorities, and the gap between compliant and noncompliant competitors in the same market. That gap is where ENDS manufacturers and retailers actually get hurt.

What FDA Actually Authorized

A marketing granted order under the PMTA pathway means FDA's Center for Tobacco Products (CTP) reviewed the specific application for the specific product — device, e-liquid formulation, nicotine concentration, and all associated labeling and marketing materials — and determined it meets the statutory standard. It does not mean the product is safe in any general sense, and FDA is explicit about this distinction in every authorization it issues. It means the agency concluded that marketing this particular product is, on balance, appropriate for the protection of the public health given the population-level tradeoffs Congress built into the statute.

That standard comes from Section 910 of the Federal Food, Drug, and Cosmetic Act, codified at 21 U.S.C. § 387j, which Congress added when it passed the Family Smoking Prevention and Tobacco Control Act of 2009. Section 910(c)(4) requires FDA to weigh whether authorization is "appropriate for the protection of the public health" — a standard reviewers and industry shorthand both call APPH — by considering risks and benefits to the population as a whole, including users of tobacco products and non-users. That last clause is the one that trips up a lot of manufacturers who assume the standard is purely about whether their product is less harmful than a cigarette. It isn't just that. FDA also has to weigh whether authorizing the product will attract new, particularly youth, users who would not otherwise have used any tobacco product.

The Regulatory Path That Got Us Here

ENDS products didn't fall under FDA's tobacco authority until the agency's 2016 deeming rule extended jurisdiction under the Tobacco Control Act to e-cigarettes, cigars, and other previously unregulated products. The key dates:

• August 8, 2016 — compliance date for the deeming rule. Only products legally marketed before February 15, 2007 counted as "grandfathered" — a category that is essentially empty for ENDS. Everything else needed a PMTA or a substantial equivalence (SE) authorization to stay on shelves legally.
• September 9, 2020 — the actual submission deadline, pushed back from the original timeline by litigation. Manufacturers with a bona fide application on file by this date could keep an existing product on the market during FDA's review — a courtesy known as enforcement discretion, not authorization.

That distinction is the one I see trip up business owners most often. Having a pending PMTA is not the same thing as having a marketing granted order. It buys you time while FDA reviews your file. It does not buy you a defense once FDA has actually acted on your application — whether that action is a grant, a marketing denial order (MDO), or a refuse-to-accept letter. The Glas authorization is a grant. Most ENDS applications FDA has acted on since 2020 have not been.

PMTA vs. the Other Tobacco Product Pathways

Most people outside this industry assume "FDA approval" is a single process. It isn't. The Tobacco Control Act actually created three distinct pathways, and which one applies to your product depends almost entirely on when it hit the market and how it compares to a legally marketed predicate.

For the overwhelming majority of ENDS manufacturers, PMTA is the only realistic route. That's precisely why the pathway carries the reputation it does in this industry: it's slow, it's expensive, and the scientific data requirements — toxicology, product design, and behavioral studies showing how the product affects both adult smokers and youth non-users — are closer to what you'd expect from a drug or device submission than a typical consumer product filing.

Why This Matters to You, Not Just to Glas

If you manufacture, distribute, or sell ENDS products, this authorization is worth reading as a signal, not just a news item. A few implications I'd flag for clients in this space:

Device-level age-gating just became a documented mitigation strategy. FDA's stated basis for the Gold and Sapphire grants leaned on access-restriction technology built into the device itself — government-ID verification, smartphone pairing, and biometric checks — as evidence the products could limit youth access despite carrying non-tobacco flavors, a profile FDA has historically treated as a youth-appeal red flag. If your own file relies on point-of-sale age verification alone, this grant is worth studying as a benchmark for what FDA now treats as credible mitigation.

The bar for a grant is real, and FDA is still issuing them selectively. Every marketing granted order FDA issues gets scrutinized by the same reviewers evaluating the backlog of applications still pending. If your PMTA is sitting in CTP's queue, the case file for a grant like this one gives you a data point on what a successful application actually demonstrated — device consistency, e-liquid stability, and youth-appeal mitigation, at minimum. If your file is thin on any of those, an authorization announcement for a competitor is a good prompt to have your regulatory counsel pressure-test your own submission before FDA gets to it.

Retailers carry exposure they often don't realize they have. A retailer selling an ENDS product without a marketing order in place — whether because the manufacturer's PMTA was denied, withdrawn, or never filed — is selling an adulterated or misbranded tobacco product under the FD&C Act, full stop. That risk sits with the retailer as much as the manufacturer. Distribution agreements should require manufacturers to represent, in writing, the current PMTA status of every SKU, and retailers should be re-verifying that status periodically rather than assuming it hasn't changed since the last order.

A grant for one brand doesn't extend to "similar" products. I get this question constantly: "our device uses the same coil and similar e-liquid formulation as [authorized product] — are we covered?" No. Authorization attaches to the specific product described in the specific application. A device with a different heating element, a different nicotine salt formulation, or even different flavor additives is a different product for PMTA purposes and needs its own review. Marketing on the theory that a competitor's grant creates cover for your comparable product is one of the more common ways I see companies end up on the receiving end of an FDA warning letter.

This is a market-access story, not a safety endorsement. FDA is careful in its own language to avoid saying an authorized ENDS product is "safe." It's appropriate for the protection of the public health relative to the alternative of that population continuing to smoke combustible cigarettes. If your marketing materials, packaging, or sales team characterize an authorization as an FDA safety approval, you're creating a misbranding problem independent of your PMTA status. I'd treat every piece of consumer-facing language tied to an authorized product as its own compliance review, not an afterthought once the marketing order arrives.

The Compliance Gap Is Where the Risk Lives

The real story in ENDS enforcement isn't the products that get authorized — it's the enormous gap between the small number of marketing granted orders FDA has issued since the September 2020 deadline and the enormous volume of ENDS products still being marketed without one. FDA's compliance and enforcement tools against that gap include warning letters, civil money penalties, product seizures, and injunctions, all of which the agency has used against ENDS manufacturers and retailers with unauthorized products still on shelves.

If you're operating in that gap right now — a pending application, an expired enforcement discretion period, or a product that was never filed — every new authorization announcement raises the visibility of the category and, with it, the odds that FDA's enforcement attention turns your direction next. I've walked clients through FDA Form 483 responses and warning letter remediation in other product categories, and the pattern holds here too: companies that treat a pending PMTA as "we're fine, we filed" without an active compliance strategy around it are the ones who get caught flat-footed when the agency acts.

What I'd Do If I Were Watching This From Inside an ENDS Company

A few concrete steps, in the order I'd actually take them:

1. Confirm your PMTA status in writing, not from memory. Pull the actual FDA correspondence — acceptance letter, filing letter, any deficiency letters — and confirm exactly which SKUs are covered and what stage each is in.
2. Audit your marketing claims against your PMTA scope. If your application covers a specific flavor and nicotine concentration, your packaging and website need to match that scope exactly. Drift between what's authorized and what's advertised is a common source of misbranding exposure.
3. Push your supply chain for documentation, not assurances. If you're a distributor or retailer, get the manufacturer's PMTA acceptance and status documentation directly rather than relying on a verbal or contractual assurance that "we're covered."
4. Watch for marketing denial orders on comparable products. An MDO issued against a similar device or formulation is often a better predictor of your own application's fate than a grant is — FDA's stated deficiencies in an MDO are about as close to a roadmap as the agency provides.
5. Build a remediation plan now, not after a warning letter. If any part of your portfolio sits in the compliance gap, decide today what you'll do if FDA acts — pull the product, file a new application, or negotiate a phase-out — rather than deciding it under the pressure of a 15-day response clock.

Manufacturers and retailers navigating FDA compliance issues more broadly, including warning letter response and remediation planning, can find more detail on how these processes typically unfold at thefdaexpert.com's FDA compliance resource page. For companies already holding a warning letter or an FDA Form 483, the practical response strategy and timeline are covered in our guide on how to respond to an FDA Form 483.

Where This Leaves the ENDS Market

This authorization does more than confirm FDA's PMTA process is still active — it opens a pathway that wasn't clearly available before: flavored ENDS products, cleared specifically on the strength of hardware-level age-gating rather than flavor restriction alone. That's a meaningful shift for any manufacturer whose PMTA strategy assumed a non-tobacco flavor was disqualifying by itself. For manufacturers with a genuinely strong file — and now, credible access-restriction technology — that's a real reason for optimism. For everyone else still marketing in the compliance gap, it's a reminder that the agency hasn't lost interest in the category — it's still working through it, one application at a time, and enforcement tends to follow close behind each new round of authorizations.

Frequently Asked Questions

What does it mean when FDA "authorizes" an ENDS product through PMTA? It means FDA's Center for Tobacco Products reviewed the specific premarket tobacco product application and issued a marketing granted order, finding that marketing that exact product is appropriate for the protection of the public health under Section 910(c)(4) of the FD&C Act. It applies only to the exact product described in the application — not to similar products from the same or other brands.

Does an ENDS PMTA authorization mean the product is FDA-approved as safe? No. FDA does not use "approval" or "safe" language for ENDS marketing authorizations. The determination is a population-level, comparative public health judgment, not a safety endorsement, and marketing materials that imply otherwise can create separate misbranding exposure.

Can I keep selling my ENDS product while my PMTA is pending? Only if FDA has extended enforcement discretion to your specific application, generally because it was timely filed by the September 9, 2020 deadline established after the 2016 deeming rule. Enforcement discretion is not authorization, and it ends the moment FDA issues a final decision — grant, denial, or refuse-to-accept — on your file.

What happens if I sell an ENDS product that never received a marketing order? The product is considered adulterated or misbranded under the FD&C Act, and both manufacturers and retailers face potential warning letters, civil money penalties, seizure, or injunction. Liability is not limited to the manufacturer that filed the application.

How is the PMTA pathway different from substantial equivalence (SE)? SE authorization compares a new product to a predicate legally marketed before February 15, 2007, and is rarely available for ENDS since almost none predate that date. PMTA requires a full scientific showing that the product is appropriate for the protection of the public health, and it's the pathway nearly all ENDS manufacturers must use.

Companies weighing whether to bring outside regulatory support into a PMTA strategy or a warning letter response may find it useful to review how to choose the right FDA consultant before engaging one.

Last updated: 2026-08-26